Compare Revvity Inc (RVTY) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Western Alliance Bancorporation — how do they compare? Revvity Inc trades at $152.05 (market cap $16.98B), while Western Alliance Bancorporation trades at $76.21 (market cap $8.24B). The key difference: Revvity Inc is far larger — about 2.1× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Western Alliance Bancorporation for 3 Days on average.
| RVTY | WAL | |
|---|---|---|
Market Cap | $16.98B | $8.24B |
Volume | 1,456,900 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $157.36 | $96.08 |
52-Week Low | $82.26 | $66.70 |
Typical Hold Time | 12 Days | 3 Days |
Enterprise Value | $19.30B | $9.76B |
Dividend Yield | 0.18% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Western Alliance Bancorporation (WAL) trades at $74.35, down 2.29% today, with a bearish technical signal but strong fundamentals including a P/E of 8.52 and net income margin of 25.43%. Recent Q2 2026 earnings missed EPS estimates at $2.36, though revenue and profitability trends remain positive. The company launched WA VenueX, an institutional financial platform, and announced a $0.42 dividend for H2-2026.
Outlook is mixed: analyst consensus is strongly bullish with a $84.33 price target, but technical indicators signal near-term pressure. Key risks include interest rate sensitivity and regulatory changes, while institutional buying and solid valuation metrics support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
